Biomarkers in autoimmune diseases of the central nervous system

Front Immunol. 2023 Apr 5:14:1111719. doi: 10.3389/fimmu.2023.1111719. eCollection 2023.

Abstract

The autoimmune diseases of the central nervous system (CNS) represent individual heterogeneity with different disease entities. Although clinical and imaging features make it possible to characterize larger patient cohorts, they may not provide sufficient evidence to detect disease activity and response to disease modifying drugs. Biomarkers are becoming a powerful tool due to their objectivity and easy access. Biomarkers may indicate various aspects of biological processes in healthy and/or pathological states, or as a response to drug therapy. According to the clinical features described, biomarkers are usually classified into predictive, diagnostic, monitoring and safety biomarkers. Some nerve injury markers, humoral markers, cytokines and immune cells in serum or cerebrospinal fluid have potential roles in disease severity and prognosis in autoimmune diseases occurring in the CNS, which provides a promising approach for clinicians to early intervention and prevention of future disability. Therefore, this review mainly summarizes the potential biomarkers indicated in autoimmune disorders of the CNS.

Keywords: CNS; Kappa free light chain; autoimmune diseases; biomarkers; cytokines; glial fibrillary acidic protein; neurofilament light chain.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmune Diseases* / diagnosis
  • Biomarkers
  • Central Nervous System
  • Glial Fibrillary Acidic Protein
  • Humans
  • Prognosis

Substances

  • Biomarkers
  • Glial Fibrillary Acidic Protein

Grants and funding

The study was supported by the National Natural Science Foundation of China (grant no. 82171777 to CZ) and the Natural Science Foundation of Tianjin Province (grant no. 20JCJQJC00280 to CZ).